Clinical trials: Bladder Cancer
Bladder Cancer
S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer
RATIONALE: Lymphadenectomy may remove tumor cells that have spread to nearby lymph nodes in patients with invasive bladder cancer.
- Trial name
- NCT01224665
- Testing
- therapeutic conventional surgery, therapeutic standard lymphadenectomy, therapeutic extended lymphadenectomy
- Where
- 35 sites in United States, Canada
- Volunteers
- 658 people
- Sponsor
- SWOG Cancer Research Network
Urothelial Cancer
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Enfortumab vedotin (or PADCEV Injection) is a treatment for cancer in the bladder lining (urothelial cancer). PADCEV Injection is now available to treat this cancer.
- Trial name
- NCT06011954
- Testing
- Enfortumab Vedotin
- Where
- 22 sites in South Korea
- Volunteers
- 228 people
- Sponsor
- Astellas Pharma Korea, Inc.
Bladder Cancer
A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)
The major purpose of this study is to examine the anti-tumor activity of the CDX-1307 vaccine regimen when it is given before and after bladder cancer surgery.
- Trial name
- NCT01094496
- Testing
- CDX-1307 Vaccine Regimen, Chemotherapy
- Where
- 17 sites in United States
- Volunteers
- 3 people
- Sponsor
- Celldex Therapeutics
Bladder Cancer, NMIBC
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
This phase II trial studies how well Pemigatinib (an orally administered inhibitor of fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer (NMIBC) patients with recurrent tumors and a prior…
- Conditions
- Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma Recurrent
- Trial name
- NCT03914794
- Testing
- Pemigatinib
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hematuria, Bladder Cancer
Role of Novel Urinary Genomic and Metablomic Markers in Diagnosis of Bladder Cancer in Patients With Hematuria
Our goal is to develop a noninvasive, fast and simple assay to detect BCa on the GeneXpert system and metablomic genes.
- Trial name
- NCT04317261
- Testing
- Xpert Bladder Cancer Monitor (Xpert Monitor) test and assay of urinary metabolomics (gene expression of CRAT and SLC)
- Where
- Egypt
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Renal Cell Carcinoma, Bladder Cancer
Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside
Immune checkpoint inhibitors (ICIs) are largely prescribed in a growing number of cancer diseases and at earlier stages (non metastatic cancer).
- Conditions
- Renal Cell Carcinoma, Bladder Cancer, MSI-H Cancer, Cancer
- Trial name
- VICKI (NCT06020651)
- Testing
- Arterial Doppler for Flow Mediated Reserve measurement
- Where
- France
- Volunteers
- 39 people
- Sponsor
- Institut Mutualiste Montsouris
Urinary Bladder Neoplasms, Prostatic Neoplasms
Lymphedema After Urologic Surgery
Lymphedema of the extremities is common after lymph node surgery in treating several forms of cancer, e.g., breast cancer. However, very little is known of the occurrence of lymphedema of the lower extremities after urologic…
- Conditions
- Urinary Bladder Neoplasms, Prostatic Neoplasms, Testicular Neoplasms, Penile Cancer
- Trial name
- NCT05264337
- Testing
- Self-reported lymphedema, Dielectric constant ratio, Limb volume
- Where
- 2 sites in Sweden
- Volunteers
- 400 people
- Sponsor
- Vastra Gotaland Region
Bladder Cancer
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Trial name
- NCT00981656
- Testing
- cisplatin, 5-fluorouracil, Mitomycin
- Where
- 13 sites in United States
- Volunteers
- 37 people
- Sponsor
- Radiation Therapy Oncology Group
Breast Neoplasms, Lung Neoplasms
Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations
BEACON (Benchmarking AI for Clinical Oncology decisioNmaking) is a prospective, multicentre, comparative, blinded, non-interventional benchmark comparing the treatment recommendations of six frontier large language models (LLMs)…
- Conditions
- Breast Neoplasms, Lung Neoplasms, Urologic Neoplasms, Prostatic Neoplasms
- Trial name
- BEACON (NCT07739121)
- Testing
- Multidisciplinary tumour boards, Frontier large language models
- Where
- 5 sites in France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Urothelial Carcinoma, Urinary Bladder Cancer
Multimodal Spectroscopy to Detect Urothelial Cancer in Urine
To facilitate the follow-up of urothelial tumors and also make them more tolerable and less invasive for patients, there is a minimally invasive and easy to perform examination which is urinary cytology on 3 samples.
- Conditions
- Urothelial Carcinoma, Urinary Bladder Cancer, Urinary Tract Cancer
- Trial name
- NCT04718948
- Testing
- Urinary Multimodal Fiber Optic Spectroscopy, Urine Cytology, Surgery
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- University of Florence
Urinary Bladder Neoplasms
A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal
The purpose of this study is to understand how the participants with high-risk non-muscle invasive bladder cancer are diagnosed, treated, and cared for in regular clinical practice in Portugal.
- Trial name
- BRITE (NCT07784387)
- Where
- Portugal
- Volunteers
- 250 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Bladder Cancer, Urinary Cancer
Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer
The purpose of the study is to see if we will be more able to tell what the risk is for bladder cancer to reoccur or worsen when genetics and risk factors are examined along with the stage and grade of the tumor.
- Conditions
- Bladder Cancer, Urinary Cancer, Nonmuscle Invasive Bladder Cancer
- Trial name
- NCT00582387
- Testing
- specimen samples, questionnaires
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Kidney Cancer, Bladder Cancer
A Study of a Side Effects and Resource Navigation Program for People With Cancer
The purpose of this study is to find out if the navigation program helps participants manage immunotherapy treatment better than usual care.
- Conditions
- Kidney Cancer, Bladder Cancer, Breast Cancer, Lung Cancer
- Trial name
- NCT07646847
- Testing
- Immunotherapy CARE Program
- Where
- 8 sites in United States
- Volunteers
- 200 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer
Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection
Phase 1 study to provide quantitative characterization of the renal elimination of ethacrynic acid and metabolites in patients with non-muscle invasive bladder cancer (NMIBC) at the time of transurethral resection of bladder tumor
- Trial name
- NCT02852564
- Testing
- Ethacrynic Acid
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Eugene Lee, MD
Bladder Cancer
RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder
The purpose of this study is to test the safety of gemcitabine applied to the bladder directly combined with different oral doses of everolimus and to assess the right doses. Gemcitabine will be given at a fixed dose.
- Trial name
- NCT01259063
- Testing
- Everolimus and Intravesical Gemcitabine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer
The Application Value of Artificial Intelligence in MRI Precision Diagnosis and Treatment of Bladder Cancer
This study was a prospective, multicenter observational clinical study, A total of 150 patients with bladder malignant tumor who was admitted to the urology department of each center for treatment and underwent electric resection…
- Trial name
- NCT05096533
- Where
- China
- Volunteers
- 150 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Bile Duct Carcinoma, Gall Bladder Cancer
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
Brief Summary: This study is for patients with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The purpose is to find out if using anti-blood vessel formation drugs after immunotherapy treatment can help…
- Conditions
- Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer, Cholangiocarcinoma
- Trial name
- SAIB (NCT07025174)
- Testing
- PD-1/CTLA-4 Dual Functional Antibody, Gemcitabine, Cisplatin, Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Bladder Cancer
Diagnostic Performance of the Vesical Imaging-Reporting and Data System (VI-RADS) in Detecting Muscle-invasive Bladder Tumour (MIBC) in Clinical Practice: Comparison With Transurethral Resection of Bladder Cancer (TURB) and Evaluation of Diagnostic Accuracy According to Tumour Location
VI-RADS was an observational, prospective, multicenter, no profit study. The aim of the study was to clarify the clinical validity of the Vesical Imaging-Reporting and Data System (VI-RADS) for the assessment of muscle invasion…
- Trial name
- VI-RADS (NCT06337591)
- Testing
- VI-RADS
- Where
- 3 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Istituto Nazionale di Ricovero e Cura per Anziani
Bladder Cancer
Study With a Newly Optical Coherence Tomography Probe for Optimizing Bladder Cancer Diagnosis and Treatment
The goal of this clinical trial is to see if a new designed optical coherence tomography catheter can be used in bladder cancer in patients undergoing a transurethral resection of a bladder tumour.
- Trial name
- BLOCT (NCT06679920)
- Testing
- Optical coherence tomography
- Where
- 2 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- Amsterdam UMC
Stomach Neoplasms, Colonic Neoplasms
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
Postoperative delirium（POD）is a common complication that can directly affect important clinical outcomes, and exert an enormous burden on patients, their families, hospitals, and public resources.
- Conditions
- Stomach Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Sigmoid Neoplasms
- Trial name
- NCT05068180
- Testing
- low-dose neuroleptanalgesia
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- RenJi Hospital